Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

Posted:
29
June 2021

J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.

Richmond Pharmacology is delighted with the acknowledgement and features at 96 in the list of 200.

The report is the first of its kind and refers to the high-growth companies founded or led by women or have management teams that are at least 50% women.

Richmond Pharmacology qualifies for the list as it was co-founded by Medical Director Dr Ulrike Lorch and has equal representation in senior management roles throughout the business.

J.P. Morgan Private Bank's list of the top 200 female-powered businesses showcases private UK businesses that have grown sales, headcount or valuation at exceptional rates. To be eligible, companies must have grown at least one of these metrics and observed this growth in the 12 months prior to 31 October 2020. In total, it analyses the 6,085 high growth companies in the UK which meet the criteria.

Dr Ulrike Lorch commenting on the success, said, "We are delighted that Richmond Pharmacology has been recognised as one of the top high-growth companies where women form a significant proportion of the founder and leadership teams. It has been a rewarding journey from founding the company to where we are now: an innovative and highly specialised team of people who play an essential part in the development of new medicines. Men and women have always had equal roles at Richmond Pharmacology - from entry positions to the boardroom - and we share our success as a collective."

Richmond Pharmacology is proud of our diverse and inclusive culture. Currently, women contribute to over half of the collective workforce. Learn more about the JP Morgan Top 200 Female Powered Businesses. Download the report here.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Making gains in drug development

September 2, 2021
Keith Berelowitz outlines the innovations in the design and delivery of clinical trials
Read more

Inclisirin hailed as a 'gamechanger' gains approval for NHS patients

September 2, 2021
This novel therapeutic drug has potential to impact millions at risk of heart attack and stroke.
Read more

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more